Literature DB >> 22797275

Neurobiological correlates of delusion: beyond the salience attribution hypothesis.

Anne Pankow1, Astrid Knobel, Martin Voss, Andreas Heinz.   

Abstract

Dopamine dysfunction is a mainstay of theories aimed to explain the neurobiological correlates of schizophrenia symptoms, particularly positive symptoms such as delusions and passivity phenomena. Based on studies revealing dopamine dysfunction in addiction research, it has been suggested that phasic or chaotic firing of dopaminergic neurons projecting to the (ventral) striatum attribute salience to otherwise irrelevant stimuli and thus contribute to delusional mood and delusion formation. Indeed, several neuroimaging studies revealed that neuronal encoding of usually irrelevant versus relevant stimuli is blunted in unmedicated schizophrenia patients, suggesting that some stimuli that are irrelevant for healthy controls acquire increased salience for psychotic patients. However, salience attribution per se may not suffice to explain anxieties and feelings of threat that often accompany paranoid ideation. Here, we suggest that beyond ventral striatal dysfunction, dopaminergic dysregulation in limbic areas such as the amygdala in interaction with prefrontal and temporal cortex may contribute to the formation of delusions and negative symptoms. Neuroleptic medication, on the other hand, appears to interfere with anticipation of reward in the ventral striatum and can thus contribute to secondary negative symptoms such as apathy and avolition.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22797275     DOI: 10.1159/000337132

Source DB:  PubMed          Journal:  Neuropsychobiology        ISSN: 0302-282X            Impact factor:   2.328


  15 in total

1.  Delusions in Alzheimer Disease: What Researchers Should Not Forget.

Authors:  Konasale M Prasad
Journal:  Am J Geriatr Psychiatry       Date:  2019-01-09       Impact factor: 4.105

2.  Karl Jaspers and the genesis of delusions in schizophrenia.

Authors:  Mario Maj
Journal:  Schizophr Bull       Date:  2013-01-11       Impact factor: 9.306

3.  Clinicopathological Study of Patients With C9ORF72-Associated Frontotemporal Dementia Presenting With Delusions.

Authors:  Shunichiro Shinagawa; Georges Naasan; Anna M Karydas; Giovanni Coppola; Mochtar Pribadi; William W Seeley; John Q Trojanowski; Bruce L Miller; Lea T Grinberg
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-10-23       Impact factor: 2.680

4.  IQ, the Urban Environment, and Their Impact on Future Schizophrenia Risk in Men.

Authors:  Timothea Toulopoulou; Marco Picchioni; Preben Bo Mortensen; Liselotte Petersen
Journal:  Schizophr Bull       Date:  2017-09-01       Impact factor: 9.306

5.  Two-channel Near-infrared Spectroscopic Analysis of Association of Paranoia Symptoms with Prefrontal Activation.

Authors:  Kazuki Hirao
Journal:  Clin Psychopharmacol Neurosci       Date:  2014-12-26       Impact factor: 2.582

6.  Reduced dopamine transporter expression in the amygdala of subjects diagnosed with schizophrenia.

Authors:  Matej Markota; Jessica Sin; Harry Pantazopoulos; Rebecca Jonilionis; Sabina Berretta
Journal:  Schizophr Bull       Date:  2014-06-16       Impact factor: 9.306

7.  Linking unfounded beliefs to genetic dopamine availability.

Authors:  Katharina Schmack; Hannes Rössler; Maria Sekutowicz; Eva J Brandl; Daniel J Müller; Predrag Petrovic; Philipp Sterzer
Journal:  Front Hum Neurosci       Date:  2015-09-30       Impact factor: 3.169

8.  Differences in gray matter volume corresponding to delusion and hallucination in patients with schizophrenia compared with patients who have bipolar disorder.

Authors:  Jinuk Song; Doug Hyun Han; Sun Mi Kim; Ji Sun Hong; Kyung Joon Min; Jae Hoon Cheong; Bung Nyun Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2015-05-18       Impact factor: 2.570

9.  Total testosterone and neuropsychiatric symptoms in elderly men with Alzheimer's disease.

Authors:  James R Hall; April R Wiechmann; Rebecca L Cunningham; Leigh A Johnson; Melissa Edwards; Robert C Barber; Meharvan Singh; Scott Winter; Sid E O'Bryant
Journal:  Alzheimers Res Ther       Date:  2015-05-01       Impact factor: 6.982

10.  Ventral striatum gray matter density reduction in patients with schizophrenia and psychotic emotional dysregulation.

Authors:  Katharina Stegmayer; Helge Horn; Andrea Federspiel; Nadja Razavi; Tobias Bracht; Karin Laimböck; Werner Strik; Thomas Dierks; Roland Wiest; Thomas J Müller; Sebastian Walther
Journal:  Neuroimage Clin       Date:  2013-12-27       Impact factor: 4.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.